Study aim: Evaluation the effect of Trifluoperazine in treatment of patients with confirmed COVID- 19 Design: Clinical trial with control group with parallel, Open labeled, Randomised Settings and conduct: Clinical trials will be conducted at the Valiasr Medical-Educational Center affiliated to Birjand University of Medical Sciences on approved COVID-19 patients. Patients are treated in two groups. The study will be performed at the beginning of hospitalization. Participants/Inclusion and exclusion criteria: Inclusion and exclusion criteria in study: Patients who have been confirmed with the Real Time PCR test for COVID-19 disease or patients who show evidence of lung involvement on CT scans. The desire to participate in the study Age over 12 years Hospitalization in the department dedicated to patients with COVID-19 Lack of confirmed allergy to triflurpazine Absence of liver disease Over 65 years of age if dementia-related psychosis is not present Lack of viral and bacterial infections Absence of pregnancy in women Patients with benign prostatic hyperplasia Patients with intestinal obstruction Patients with blood disorders and bone marrow disorders Patients with severe central nervous system weakness or coma Intervention groups: Control group:Patients treated with hydroxychloroquine and, if necessary, according to the approved treatment protocol, kaletra and ribavirin are added to the treatment. Case group:In addition to treating hydroxychloroquine, trifluoprazine is given at a dose of 2 mg twice daily for 14 days. In this group, if necessary, according to the approved treatment protocol, Kaletra and ribavirin are added to the treatment. Main outcome variables: Determination of therapeutic effects of trifluoprazine in patients with COVID19: -Respiratory function of the lungs. -Reducing the patient's inflammatory responses. -Reduction of the patient's hospitalization period. -Reduce mortality